vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Healthpeak Properties (DOC). Click either name above to swap in a different company.

Healthpeak Properties is the larger business by last-quarter revenue ($719.4M vs $487.7M, roughly 1.5× CLOVER HEALTH INVESTMENTS, CORP.). Healthpeak Properties runs the higher net margin — 73.2% vs -10.1%, a 83.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 3.1%). Healthpeak Properties produced more free cash flow last quarter ($357.0M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 8.9%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Healthpeak Properties, Inc. is an American real estate investment trust that invests in real estate related to the healthcare industry including senior housing, life science, and medical offices. It was organized in 2007 in Maryland and headquartered in Denver, Colorado with offices in Irvine, Nashville and San Francisco. As of December 31, 2019, the company owned interests in 617 properties.

CLOV vs DOC — Head-to-Head

Bigger by revenue
DOC
DOC
1.5× larger
DOC
$719.4M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+41.7% gap
CLOV
44.7%
3.1%
DOC
Higher net margin
DOC
DOC
83.3% more per $
DOC
73.2%
-10.1%
CLOV
More free cash flow
DOC
DOC
$426.0M more FCF
DOC
$357.0M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
8.9%
DOC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
DOC
DOC
Revenue
$487.7M
$719.4M
Net Profit
$-49.3M
$114.0M
Gross Margin
Operating Margin
-10.1%
17.4%
Net Margin
-10.1%
73.2%
Revenue YoY
44.7%
3.1%
Net Profit YoY
-123.2%
2406.4%
EPS (diluted)
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
DOC
DOC
Q4 25
$487.7M
$719.4M
Q3 25
$496.6M
$705.9M
Q2 25
$477.6M
$694.3M
Q1 25
$462.3M
$702.9M
Q4 24
$337.0M
$698.0M
Q3 24
$331.0M
$700.4M
Q2 24
$356.3M
$695.5M
Q1 24
$346.9M
$606.6M
Net Profit
CLOV
CLOV
DOC
DOC
Q4 25
$-49.3M
$114.0M
Q3 25
$-24.4M
$-117.1M
Q2 25
$-10.6M
$31.7M
Q1 25
$-1.3M
$42.8M
Q4 24
$-22.1M
$4.5M
Q3 24
$-9.2M
$85.9M
Q2 24
$7.4M
$146.0M
Q1 24
$-19.2M
$6.7M
Gross Margin
CLOV
CLOV
DOC
DOC
Q4 25
Q3 25
58.6%
Q2 25
60.2%
Q1 25
61.1%
Q4 24
60.3%
Q3 24
24.5%
60.0%
Q2 24
30.3%
60.6%
Q1 24
23.6%
59.8%
Operating Margin
CLOV
CLOV
DOC
DOC
Q4 25
-10.1%
17.4%
Q3 25
-4.9%
9.2%
Q2 25
-2.2%
5.7%
Q1 25
-0.3%
7.7%
Q4 24
-6.4%
-2.2%
Q3 24
-2.7%
14.1%
Q2 24
2.0%
22.3%
Q1 24
-6.5%
3.7%
Net Margin
CLOV
CLOV
DOC
DOC
Q4 25
-10.1%
73.2%
Q3 25
-4.9%
-16.6%
Q2 25
-2.2%
4.6%
Q1 25
-0.3%
6.1%
Q4 24
-6.6%
0.7%
Q3 24
-2.8%
12.3%
Q2 24
2.1%
21.0%
Q1 24
-5.5%
1.1%
EPS (diluted)
CLOV
CLOV
DOC
DOC
Q4 25
$0.16
Q3 25
$-0.17
Q2 25
$0.05
Q1 25
$0.06
Q4 24
$0.02
Q3 24
$0.12
Q2 24
$0.21
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
DOC
DOC
Cash + ST InvestmentsLiquidity on hand
$78.3M
$467.5M
Total DebtLower is stronger
$9.8B
Stockholders' EquityBook value
$308.7M
$7.5B
Total Assets
$541.0M
$20.3B
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
DOC
DOC
Q4 25
$78.3M
$467.5M
Q3 25
$91.0M
Q2 25
$89.4M
Q1 25
$70.6M
Q4 24
$194.5M
$119.8M
Q3 24
$288.0M
$180.4M
Q2 24
$254.8M
$106.9M
Q1 24
$208.3M
$101.8M
Total Debt
CLOV
CLOV
DOC
DOC
Q4 25
$9.8B
Q3 25
$9.1B
Q2 25
$9.0B
Q1 25
$8.9B
Q4 24
$8.7B
Q3 24
$8.6B
Q2 24
$8.6B
Q1 24
$8.8B
Stockholders' Equity
CLOV
CLOV
DOC
DOC
Q4 25
$308.7M
$7.5B
Q3 25
$340.9M
$7.6B
Q2 25
$344.2M
$7.9B
Q1 25
$336.1M
$8.2B
Q4 24
$341.1M
$8.4B
Q3 24
$342.2M
$8.6B
Q2 24
$324.9M
$8.8B
Q1 24
$292.5M
$8.9B
Total Assets
CLOV
CLOV
DOC
DOC
Q4 25
$541.0M
$20.3B
Q3 25
$559.7M
$19.6B
Q2 25
$575.0M
$19.8B
Q1 25
$583.7M
$19.8B
Q4 24
$580.7M
$19.9B
Q3 24
$653.0M
$20.0B
Q2 24
$674.2M
$20.2B
Q1 24
$671.8M
$20.5B
Debt / Equity
CLOV
CLOV
DOC
DOC
Q4 25
1.31×
Q3 25
1.20×
Q2 25
1.14×
Q1 25
1.08×
Q4 24
1.04×
Q3 24
1.00×
Q2 24
0.98×
Q1 24
0.99×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
DOC
DOC
Operating Cash FlowLast quarter
$-66.9M
$1.3B
Free Cash FlowOCF − Capex
$-69.0M
$357.0M
FCF MarginFCF / Revenue
-14.1%
49.6%
Capex IntensityCapex / Revenue
0.4%
124.4%
Cash ConversionOCF / Net Profit
10.99×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
DOC
DOC
Q4 25
$-66.9M
$1.3B
Q3 25
$12.1M
$315.0M
Q2 25
$5.4M
$363.5M
Q1 25
$-16.3M
$279.4M
Q4 24
$34.8M
$1.1B
Q3 24
$50.0M
$318.2M
Q2 24
$44.8M
$316.2M
Q1 24
$25.9M
$152.6M
Free Cash Flow
CLOV
CLOV
DOC
DOC
Q4 25
$-69.0M
$357.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
$333.7M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
DOC
DOC
Q4 25
-14.1%
49.6%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
47.8%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
DOC
DOC
Q4 25
0.4%
124.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
105.6%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
DOC
DOC
Q4 25
10.99×
Q3 25
Q2 25
11.48×
Q1 25
6.52×
Q4 24
235.43×
Q3 24
3.71×
Q2 24
6.04×
2.17×
Q1 24
22.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons